Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193346 | 1.00 | LGALS8 (0.35) | LGALS8ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL16156839 | 0.90 | ABCB1 (0.36) | LGALS8ALDH1A1BCHE | |
| SCHEMBL16193347 | 0.86 | LGALS8 (0.38) | LGALS8ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL14906019 | 0.85 | LGALS8 (0.34) | LGALS8ALDH1A1BCHE | |
| SCHEMBL16156835 | 0.85 | LGALS8 (0.34) | LGALS8ALDH1A1BCHE | |
| SCHEMBL16156791 | 0.84 | LGALS8 (0.33) | LGALS8ALDH1A1BCHE | |
| SCHEMBL16156885 | 0.84 | LTA4H (0.35) | LGALS8ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL14905962 | 0.84 | LTA4H (0.35) | LGALS8ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL14905934 | 0.84 | LGALS8 (0.33) | LGALS8ALDH1A1BCHE | |
| SCHEMBL16193367 | 0.84 | LGALS8 (0.33) | LGALS8ALDH1A1LMNAPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493501-B2 | Methyltransferase inhibitors for treating cancer | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2771343-B1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | SLOAN KETTERING INST CANCER (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20140303106-A1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2014-10-09 | — | — | US | disclosed |
| WO-2013063417-A1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303106-A1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GNMT, AS3MT, TPMT | LGALS8 3668/4885ALDH1A1 819/4885LMNA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.